Abstract: A method for treating cerebral vascular diseases in a human or non-human animal is disclosed. The method involves inhibiting 20-HETE synthesizing enzyme activity sufficiently to increase or prevent a decrease in cerebral blood flow in the human or non-human animal.

Abstract: A therapeutic agent for hypertension, which comprises as an active ingredient a compound capable of inhibiting Na+/Ca2+ exchanger 1.

Abstract: A therapeutic agent for hypertension, which comprises as an active ingredient a compound capable of inhibiting Na+/Ca2+ exchanger 1.

Abstract: A therapeutic agent for chronic kidney diseases, which comprises as an active ingredient a compound capable of inhibiting Na+/Ca2+ exchanger 1.

Abstract: A method for treating cerebral vascular diseases in a human or non-human animal is disclosed. The method involves inhibiting 20-HETE synthesizing enzyme activity sufficiently to increase or prevent a decrease in cerebral blood flow in the human or non-human animal.

Abstract: A hydroxyeicosenoic acid analog represented by the following Formula (I), the bond ? represents a cis-vinylene group or an ethynylene group; Y represents CH2, O or S(O)p wherein p is 0, 1 or 2; m represents an integer of 1 to 4 inclusive; n represents an integer of 0 to 3 inclusive; the sum of m and n is an integer of 3 to 7 inclusive; R1 represents a C1-4 alkyl group or a C3-8 cycloalkyl group; R2 represents a hydrogen atom or a methyl group; R3 represents COR4, a nitrile group, a halogen atom, a tetrazole group or a thiazolidinedione group; R4 represents OR6, NHR6, N(OH)R6, NHSO2R5, glycerol or functionalized glycerols; R5 represents a C1-15 alkyl group, a C6-10 aryl group or a C7-14 aryl group substituted with alkyl groups, halogens or amino groups; R6 represents a hydrogen, a C1-10 alkyl group or a C1-10 alkyl group substituted with a hydroxyl group, or a pharmaceutically acceptable salt or hydrate thereof. The compounds of the present invention are useful as an elastase release inhibitor.

Abstract: A hydroxyfattysulfonic acid analog represented by Formula (I): wherein X is an ethylene group, a vinylene group or an ethynylene group; Y is an ethylene group, a vinylene group, an ethynylene group, OCH2 or S(O)pCH2 wherein p is 0, 1 or 2; m is an integer of 1 to 5 inclusive; n is an integer of 0 to 4 inclusive; R1 is a C1-8 alkyl group, a C3-8 cycloalkyl group, a C1-4 alkyl group substituted with a C3-8 cycloalkyl group, a C1-4 alkyl group substituted with an aryl group or a C1-4 alkyl group substituted with an aryloxy group; R2 is a hydrogen atom or a methyl group; R1 and R2 together with the carbon atom to which they are attached may form a C3-8 cycloalkyl group; R3 is a hydrogen atom or a C2-8 acyl group; R4 is OR5 or NHR6, wherein R5 is a hydrogen atom, a C1-4 alkyl group, an alkali metal, an alkaline earth metal or an ammonium group and R6 is a hydrogen atom or a C1-4 alkyl group; or a pharmaceutically acceptable salt or a hydrate thereof.

Abstract: A sleep-inducing preparation which comprises as an effective ingredient a prostaglandin derivative represented by the formula: wherein X is a halogen atom, Y is a group represented by (CH2)m, a cis-vinylene group or a phenylene group, Z is an ethylene group, a trans-vinylene group, OCH2 or S(O)nCH2, R1 is a C3-10 cycloalkyl group, a C3-10 cycloalkyl group substituted with C1-4 alkyl group(s), a C4-13 cycloalkylalkyl group, a C5-10 alkyl group, a C5-10 alkenyl group, a C5-10 alkynyl group or a bridged cyclic hydrocarbon group, R2 is a hydrogen atom, a C1-10 alkyl group or a C3-10 cycloalkyl group, m is an integer of 1 to 3, and n is 0, 1 or 2, a pharmaceutically acceptable salt thereof or a hydrate thereof.

Abstract: A prostaglandin derivative represented by the formula: wherein X is a halogen atom, n is an integer of 1 to 5, R1 is a C3-10 cycloalkyl group, a C3-10 cycloalkyl group substituted with C1-4 alkyl group(s), a C4-13 cycloalkylalkyl group, a C5-10 alkyl group, a C5-10 alkenyl group, a C5-10 alkynyl group or a bridged cyclic hydrocarbon group, and R2 is a hydrogen atom, a C1-10 alkyl group or a C3-10 cycloalkyl group, or a pharmaceutically acceptable salt thereof.

Abstract: A 4-tetrahydropyridylpyrimidine compound represented by formula (I): wherein Ar represents a phenyl group substituted with 1 to 3 substituents selected from a halogen atom, an alkyl group having 1 to 5 carbon atoms, an alkoxy group having 1 to 5 carbon atoms, and a trifluoromethyl group, a phenyl group, a thienyl group or a furanyl group; R1 represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an amino group or an amino group substituted with 1 or 2 alkyl groups having 1 to 5 carbon atoms; R2 represents an alkyl group having 1 to 5 carbon atoms, a cycloalkylalkyl group having 4 to 7 carbon atoms, an alkenyl group having 2 to 5 carbon atoms or an alkynyl group having 2 to 5 carbon atoms; and X1, X2, and X3, which may be the same or different, each represent a hydrogen atom, a halogen atom, an alkyl group having 1 to 5 carbon atoms, an alkoxy group having 1 to 5 carbon atoms, an alkylthio group having 1 to 5 carbon atoms, an amino group or an amino group substituted with 1 or

Abstract: 2-nitroxyethyl (+)apovincaminate is used as an agent for relieving disturbance of consciousness and as a narcotic antagonist.

Abstract: An electric far-infrared heater has a plate-like porous metallic panel formed by an electroforming process installed in a box-like housing over an electric heating element therein. The panel is heated by the element and has its outer surface covered by a porous ceramic far-infrared emitting layer of Al.sub.2 O.sub.3, TiO.sub.2, Cr.sub.2 O.sub.3, MgO, ZrO.sub.2, SiO.sub.2 or mixtures thereof. A stream of gas supplied to the interior of the housing is heated by the element and passes through the porous panel and far-infrared layer for discharge onto the object being heated.

Abstract: An infrared electric panel heater includes an open side covered by a sintered or electroformed porous metallic panel. An electric sheathed heating element is installed in the housing in contact with the inner surface of the porous panel. The outer surface of the porous panel is substantially entirely covered with a ceramic layer, selected from the group consisting of Al.sub.2 O.sub.3, TiO.sub.2, Cr.sub.2 O.sub.3, Mg O, ZrO.sub.2, SiO.sub.2 and mixture thereof, which emits far-infrared rays when heated.

Abstract: Improvements in apparatus for the manufacture of a cable by laying or assemblying pre-twisted outer strands around a pre-twisted core. For smooth transmission of the pre-twist through the core length from a pay-out reel to a laying die, a series of interspaced pairs of opposed guide rollers are disposed along the path of the core to engage the same therebetween. Further, for smooth transmission of the pre-twists through the lengths of the outer strands from respective pay-out reels to the laying die, a series of interspaced tapered guide rollers are disposed along a curve in the path of each outer strand. At least some of the tapered guide rollers are set an an angle to the axial direction of the outer strand being fed thereover and, preferably, further to the direction normal to the vertical plane containing the curve in the outer strand path.